Loading stock data…
Novo Nordisk B A/S (NOVO-B.CO)
kr292.00-6.95 (-2.32%)
Market ClosedLast close Sep 8
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novo Nordisk A/S in the Healthcare sector is trading at $292.00 with a market capitalization of $1.3T. Wall Street consensus targets $309.30 (23 analysts), implying a +5.9% move over the next 12 months. The stock is currently 29% below its 52-week high of $409.95, remaining 0.2% above its 200-day moving average. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +5.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (DKK) | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Total Revenue | kr76.86B↑ | kr74.98B↓ | kr79.14B↓ | kr96.82B↑ | kr78.49B |
| Gross Profit | kr64.01B↑ | kr57.07B↓ | kr64.00B↓ | kr83.22B↑ | kr61.39B |
| Operating Income | kr33.45B↑ | kr23.68B↓ | kr31.74B↓ | kr59.62B↑ | kr27.06B |
| Net Income | kr26.50B↑ | kr20.01B↓ | kr26.89B↓ | kr48.56B↑ | kr20.99B |
Peer Comparison
JNJUNHPFE
Fundamentals
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabet...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
kr1.29T
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
11.12
Beta
Defensive asset. Lower volatility than the S&P 500.
0.34
Div Yield
Strong income play. Yield provides a meaningful total return floor.
391.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
59.81%
Volume
Today's trading volume
3.69M
Recent News
Sector Update: Healthcare Stocks Fall Late Afternoon
Healthcare stocks declined late Tuesday afternoon with the NYSE Healthcare Index falling 2.5% and th
Sector Update: Healthcare Stocks Fall Tuesday Afternoon
Healthcare stocks declined Tuesday afternoon, with the NYSE Healthcare Index falling 2.4% and the St
GLP1 Drugs Work for Kids, Says Novo Nordisk. They Could Be Another Huge Market.
Novo announced successful results from a Phase 3 study of its injectable GLP1 drug Wegovy in obese children aged six to 12.
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore?
Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe.
Why the CEO of Wegovy maker Novo Nordisk isn't yet sold on the peptide craze
Novo Nordisk's new CEO sounds the alarm on peptides.